Introduction {#S1}
============

DNA topoisomerases are evolutionarily conserved nuclear enzymes that have major functions in the cell cycle, including DNA replication, recombination, and chromosome segregation ([@R34]; [@R53]). The two major families of topoisomerases are differentiated by the type of enzymatic reactions each performs. Type I topoisomerases produce protein-associated single strand breaks in DNA and relieve supercoiling tension by free rotation of the cut strand around the intact strand. Type II topoisomerases produce protein-associated DNA double-strand breaks (dsb) and are capable of passing an intact DNA duplex through the protein-associated dsb. Thus, only type II topoisomerases can separate knotted and intertwined DNA molecules. Mammalian species express two topoII isoforms: α and β. Each isoform is encoded by a separate gene located on different human chromosomes and can be distinguished by mass ([@R2]; [@R11]; [@R12]). The two isoforms share \~70% homology at the amino acid level, and exist as homodimeric enzymatic complexes with similar catalytic activities, although α/β heterodimers have been observed ([@R26]; [@R9]).

TopoIIβ is non-essential and constitutively expressed, whereas topoIIα is an essential gene maximally expressed in G~2~ and M ([@R25]; [@R27]; [@R1]). TopoII activity is required for chromosome condensation, decatenation of intertwined daughter DNA duplexes, and centromere resolution ([@R54]; [@R14]; [@R42]). Catenations between chromatid arms are removed prior to mitosis, while centromeric catenations persist up to the metaphase/anaphase transition ([@R20]; [@R48]).

DNA and topoIIα form a reversible, covalent complex, often referred to as the cleavage complex ([@R11]; [@R15]). TopoII-inhibiting drugs interfere with various stages of the catalytic cycle, and are therefore divided into two classes: poisons and catalytic inhibitors. TopoII poisons such as doxorubicin and etoposide stabilize the cleavage complex, which may block DNA replication forks or transcriptional machinery and create dsbs ([@R55]). Upon proteolysis of the stabilized cleavage complex, the dsb is exposed; thus, these drugs are used clinically to treat cancers that typically over-express topoII ([@R43]; [@R29]; [@R38]).

In contrast, catalytic inhibitors prevent the formation of the cleavage complex by intercalating into DNA and inhibiting topoII binding, or by stabilizing topoII in a closed-clamp conformation after the ligation step of the catalytic cycle ([@R49]; [@R47]). Therfore, topoII catalytic inhibitors are primarily used in the clinical setting as an adjunct to reduce the cardiotoxicity of topoII poisons ([@R41]). The ability of topoII catalytic inhibitors to protect against the toxicity of topoII poisons implies that poisons and catalytic inhibitors have very different effects on topoII activity, DNA binding, and chromatin structure.

Studies using topoII catalytic inhibitors suggest that G~2~ cells monitor the catenation state of intertwined sister chromatids following DNA replication and actively delay progression into mitosis pending sufficient chromatid decatenation ([@R22]; [@R18]). A subset of chromatid catenations appear to be organized in the centromere, and these catenations are not separated until the onset of anaphase ([@R20]). Thus, the decatenation G~2~ checkpoint appears to monitor the sufficiency of decatenation along the chromosomal arms, not its completion. The expression of an active decatenation G~2~ checkpoint was supported by evidence that the G~2~ delay in cells with catalytic inhibition of topoII was dependent upon BRCA1 expression and could be overridden by caffeine ([@R18]). BRCA1 may be required to activate topoIIα by ubiquitylation ([@R39]). Other studies have implicated ATR, ATM, Plk1, WRN, MDC1, and Chk1 in the decatenation G~2~ checkpoint ([@R10]; [@R46]; [@R19]; [@R24]; [@R40]). Although the presence of a decatenation G~2~ checkpoint that is independent of DNA damage has been supported by a variety of studies ([@R16]; [@R44]; [@R21]), the concept is still controversial since ICRF-193 has been shown to activate DNA damage signaling in some cancer cell lines ([@R44]; [@R45]).

The work described herein utilizes normal human diploid fibroblast (NHDF) lines isolated from three different individuals and depleted of either topoIIα or topoIIβ. These data support a distinction between the decatenation and DNA damage G~2~ checkpoints, and suggest that topoIIα plays a role in maintaining genomic stability through chromatid decatenation and decatenation G~2~ checkpoint signaling.

Results {#S2}
=======

TopoIIα is required for decatenatory activity {#S3}
---------------------------------------------

As there are two forms of topoII in mammals, it was necessary to determine the individual contribution of each isoform to cellular decatenatory activity. NHDFs were depleted of topoIIα or topoIIβ using siRNA and assayed 48 h after electroporation. Representative western blots for three NHDF lines are shown ([Fig. 1A](#F1){ref-type="fig"}, [S1A](#SD1){ref-type="supplementary-material"}). Nuclear extracts were prepared and assayed for *in vitro* decatenatory activity upon catenated circular DNA molecules isolated from trypanosome kinetoplasts (kDNA). Incubation of kDNA with NHDF nuclear extracts released free mini-circles and intermediate mobility DNA species that likely represent catenated dimers or trimers, while decatenatory activity was inhibited by the topoII catalytic inhibitor, ICRF-193 ([Fig. 1B](#F1){ref-type="fig"}). Furthermore, decatenatory activity was severely reduced in nuclear extracts isolated from topoIIα-depleted cells relative to cells that were electroporated with non-targeting control (NTC) siRNA ([Fig. 1B](#F1){ref-type="fig"}, [S1B](#SD1){ref-type="supplementary-material"}). TopoIIβ-depleted nuclear extracts displayed similar activity to that of the NTC extracts. Collectively, these results suggest that topoIIα accounts for the majority of decatenatory activity in actively growing NHDFs.

Catalytic inhibition of topoII with ICRF-193 inhibits mitotic entry {#S4}
-------------------------------------------------------------------

Catalytic inhibitors of topoII are thought to induce a decatenation G~2~ checkpoint and prevent entry into mitosis. In order to verify that the decatenation G~2~ checkpoint was effective in NHDFs, live-imaging bright-field microscopy was employed. Mitotic NHDFs were clearly distinguishable from interphase fibroblasts under bright-field microscopy due to their round morphology, whereas interphase fibroblasts were flat, thin, and elongated. Time-lapse images were collected every two minutes and full length movies can be viewed at our laboratory website (<http://top2a.med.unc.edu/jackie/home.html>). Representative images at 0, 1, 4, and 12 h after addition of DMSO or ICRF-193 are shown, with black arrows designating mitotic cells ([Fig. 2](#F2){ref-type="fig"}). NHDFs exposed to DMSO entered and exited mitosis throughout the length of the movie, whereas catalytic inhibition of topoIIα with 4 μM ICRF-193 allowed mitotic exit, but not mitotic entry. Flow cytometric analysis of cellular DNA content further demonstrated that greater than 50% of fibroblasts were in G~2~ after 28 h incubation with ICRF-193 ([Fig. S2](#SD2){ref-type="supplementary-material"}). These results indicated that mitotic entry was arrested in NHDFs upon catalytic inhibition of topoII.

ICRF-193 does not induce detectable DNA damage in NHDFs {#S5}
-------------------------------------------------------

A few studies have detected DNA damage (particularly dsbs) upon inhibition of topoII with ICRF-193. In order to verify that catalytic inhibition of topoIIα with ICRF-193 did not induce a DNA damage response in NHDFs, immunofluorescence and flow cytometric studies were performed to determine the levels of a common DNA damage marker, γH2AX. In [Figure 3A](#F3){ref-type="fig"}, representative images are shown for NHF1-hTERTs treated for 15 min with DMSO, ICRF-193, or etoposide and stained for γH2AX by immunofluorescence. Etoposide-treated NHDFs displayed many γH2AX foci after 15 min, whereas no detectable γH2AX foci were present after ICRF-193 treatment. Flow cytometric studies were performed in parallel to quantify γH2AX positive NHDFs ([Fig. 3B](#F3){ref-type="fig"}). All NHDFs exhibited an increase in γH2AX positive cells after etoposide treatment, whereas ICRF-193 treatment induced no detectable γH2AX staining above background levels. Similar results have been observed by western immunoblot analysis in lymphoblast and fibroblast cell lines ([@R10]). The slight increase in γH2AX staining seen at the 6 h time point was determined to be statistically insignificant by a Student's t-test, and was the result of an idiosyncratic response by the NHF3-hTERT cell line. NHF3-hTERTs also displayed higher background γH2AX staining and hypersensitivity to both ICRF-193 and topoIIα depletion (Zhou and Kaufmann, unpublished data and [Fig. 7C](#F7){ref-type="fig"}), suggesting that these cells may display higher levels of cellular stress in culture. Overall, these results indicate that ICRF-193 does not induce dsb formation in NHDFs.

TopoIIα depletion ablates the decatenation G~2~ checkpoint response, but has no effect on the DNA damage G~2~ checkpoint response {#S6}
---------------------------------------------------------------------------------------------------------------------------------

ICRF-193 inhibits topoII function by holding the enzyme as a closed clamp that is tethered to DNA but incapable of DNA strand passage, thus rendering cells unable to remove DNA catenations ([@R55]; [@R47]; [@R30]). Previous studies have suggested that G~2~ cells sense the presence of entangled and/or catenated chromatids and actively delay mitosis until decatenation is sufficiently advanced to permit mitotic cell division ([@R22]). Therefore, conditions that slow the rate of chromatid decatenation should reduce the rate of mitotic entry by causing a G~2~ delay, leading to an increase in the G~2~ cell fraction.

To test this hypothesis, fibroblasts were electroporated with NTC or topoIIα siRNA and analyzed for their ability to arrest in G~2~ and exit mitosis upon DNA damage (IR) or catalytic inhibition (ICRF-193) of topoII. Representative flow cytometry plots of NHF1-hTERTs are shown in [Figure 4A](#F4){ref-type="fig"}. In both NTC and topoIIα-depleted fibroblasts, IR produced a 75--80% average reduction in mitotic index 2 h after treatment ([Fig. 4B](#F4){ref-type="fig"}). This reduction of the mitotic index has previously been thought to reflect both an arrest of G~2~ cells and the exit of mitotic cells into interphase after irradiation. The NTC-depleted fibroblasts retained a functional decatenation G~2~ checkpoint; they displayed a mean 60% reduction in mitotic index upon ICRF-193 treatment. In contrast, topoIIα-depleted fibroblasts displayed a mean 257% increase in mitotic index upon treatment with ICRF-193. These results suggested that while topoIIα depletion did not significantly alter the DNA damage G~2~ checkpoint response, it ablated the decatenation G~2~ checkpoint response.

One explanation for the increase in topoIIα-depleted mitotic cells after ICRF-193 treatment was that NHDFs were delaying mitotic exit due to the persistence of centromeric DNA catenations ([@R54]; [@R14]; [@R20]; [@R48]). This effect might be enhanced upon further inhibition of residual topoIIα and topoIIβ with ICRF-193, thus prolonging the amount of time spent in mitosis. If the amount of time NHDFs spent in mitosis was altered by a decrease in topoIIα activity, it was necessary to monitor the G~2~/M transition by examining the mitotic entry rate (MER) of NHDFs in order to discriminate between the G~2~/M and spindle assembly checkpoint mechanisms. NHDFs were collected over time in colcemid, a microtubule polymerization inhibitor that arrests cells with an intact spindle assembly checkpoint at metaphase. This assay allows for a strict examination of the G~2~ to M transition, and calculation of the MER by linear regression provides a quantitative measure of decatenation G~2~ checkpoint function.

NTC-, topoIIα-, and topoIIβ-depleted fibroblast lines displayed an increase in the percentage of mitotic cells over time in the presence of DMSO and colcemid ([Fig. 4C](#F4){ref-type="fig"}, [S3](#SD3){ref-type="supplementary-material"}). In contrast, when topoII activity was inhibited with ICRF-193 in NTC- or topoIIβ-depleted fibroblasts, MERs were approximately zero. Surprisingly, the topoIIα-depleted fibroblasts continued to enter mitosis, regardless of the presence of ICRF-193. Comparison of MERs indicated that topoIIα-depleted cells entered mitosis at a rate that was approximately half that of NTC-treated fibroblasts ([Fig. 4D](#F4){ref-type="fig"}). Mitotic entry in the topoIIα-depleted NHF1-hTERTs was independently verified by time-lapse bright-field microscopy and full length videos can be viewed at the laboratory's website (<http://top2a.med.unc.edu/jackie/home.html>). Quantification of G~2~ fractions in this assay also revealed that a significant G~2~ accumulation occurred upon topoIIα depletion or catalytic inhibition ([Fig. S4](#SD4){ref-type="supplementary-material"}).

Several attempts to correct the phenotype of NHDFs by over-expressing a siRNA-resistant form of topoIIα were unsuccessful due to the toxicity of topoIIα over-expression. Therefore, a second siRNA directed towards topoIIα was tested in the mitotic entry assay. The results confirmed that the observed phenotype was not due to off-target effects of either siRNA ([Fig. S5](#SD5){ref-type="supplementary-material"}). Taken together, these data suggest that a catalytically inactive topoIIα protein is required to arrest cells in G~2~ during incubation with ICRF-193 and prevent mitotic entry in the presence of entangled/catenated chromosomes. Furthermore, these results indicate that the decatenation G~2~ checkpoint does not sense DNA catenations *per se*, but rather senses the catalytically inactive form of topoIIα.

TopoIIα depletion does not affect the ability of NHDFs to synthesize DNA {#S7}
------------------------------------------------------------------------

Since topoIIα protein expression is cell cycle-dependent and a previous report suggested that type II topoisomerases are required for the completion of S phase in budding yeast ([@R7]), it was important to determine whether topoIIα played a role in DNA synthesis and/or the completion of S phase in NHDFs. If DNA replication or completion of S phase were impaired, this could slow down the MERs. Flow cytometry was utilized to determine the capacity of topoIIα-depleted cells to incorporate the thymidine analog BrdU during S phase and representative flow cytometry profiles are shown ([Fig. 5A](#F5){ref-type="fig"}). While topoIIα-depleted cells displayed normal levels of BrdU incorporation, there were slightly fewer fibroblasts present in S phase when compared to NTC-treated fibroblasts ([Fig. 5B](#F5){ref-type="fig"}). This difference was determined to be insignificant by Student's t-test. However, the percentage of G~2~ cells increased in topoIIα-depleted fibroblasts, suggesting that cells were indeed progressing through S phase and into G~2~. Similar results were obtained upon ICRF-193 treatment ([Fig. S6](#SD6){ref-type="supplementary-material"}) and by using synchronized fibroblasts (not shown), suggesting that topoIIα depletion or inhibition does not interfere with DNA replication or completion of S phase in NHDFs. In addition, recently published data from our laboratory has suggested that neither ATR nor Chk1 depletion affected the MERs or decatenation G~2~ checkpoint function of NHDFs ([@R10]). Similarly, no Chk1 activation was observed in response to ICRF-193 treatment. These data further support the conclusion that topoII catalytic inhibition or depletion does not induce a replicative stress response in NHDFs.

TopoIIα-depleted fibroblasts display abnormal metaphase chromosome structure {#S8}
----------------------------------------------------------------------------

Inhibition of topoII with ICRF-193 produces characteristic abnormalities in cells that evade the decatenation G~2~ checkpoint. Metaphase preparations of ICRF-193-treated cells often display under-condensed and entangled chromosomes ([@R19]). Since the results in [Figures 1B](#F1){ref-type="fig"} and [4C](#F4){ref-type="fig"} indicated that NHDFs enter mitosis in the absence of significant topoIIα activity, cytogenetic studies were performed to examine chromosome morphology. TopoIIα-depletion significantly increased the frequencies of metaphase preparations with under-condensed or entangled chromosomes, whereas topoIIβ-depleted fibroblasts displayed no significant increases in chromosomal aberrations ([Fig. 6A, 6B](#F6){ref-type="fig"}). Thus, depletion of topoIIα produced similar effects on chromosome structure as catalytic inhibition of topoII with ICRF-193.

Depletion of topoIIα increases the frequency of abnormal interphase nuclei and promotes losses and gains of the p16^INK4A^ tumor suppressor allele {#S9}
--------------------------------------------------------------------------------------------------------------------------------------------------

Although the cytogenetic experiments in [Fig. 6A/B](#F6){ref-type="fig"} established that NHDFs would enter mitosis with entangled chromosomes, it was unclear whether these cells would exit mitosis, re-enter interphase, and potentially duplicate a set of damaged or aneuploid chromosomes during subsequent rounds of DNA replication and cell division. Since entangled chromosomes may not segregate properly at anaphase, failures of segregation (non-disjunction) can generate anaphase bridges, lagging chromosomes, and/or chromosomal breakage. After restitution of interphase nuclear structure, thin bridges connecting two nuclei may be apparent or one nucleus may have two lobes. Laggard or broken chromosomes are often manifested as micronuclei. The frequencies of interphase nuclei with structural alterations such as bridges, blebs and micronuclei were therefore examined ([Fig. 6C](#F6){ref-type="fig"}). While NTC-treated fibroblasts exhibited a low frequency of nuclear abnormalities (\<5%), the frequencies of abnormalities were increased to \~33% or \~14% after depletion of topoIIα or topoIIβ, respectively ([Fig. 6D](#F6){ref-type="fig"}). These results suggested that NHDFs can exit mitosis with chromosomal mis-segregation and/or non-disjunction errors.

Abnormal chromosome segregation can lead to the loss and gain of genetic material and promote gross chromosomal rearrangements, thereby generating chromosomal instability (reviewed in [@R28]). To determine whether decreased topoIIα levels and/or activity could generate genomic instability in NHDFs, fluorescence *in situ* hybridization (FISH) probes directed towards the tumor suppressor *p16^INK4A^* genetic locus (red) and the centromere of chromosome 9 (green) were hybridized to cytogenetic preparations ([Fig. 7A](#F7){ref-type="fig"}). NHDFs with 2--4 copies of each locus were considered to retain a normal allelic copy number to account for DNA replication in log phase cells. At least 100 interphase cells were analyzed from each NHDF line. The topoIIβ-depleted fibroblasts failed to exhibit any significant allelic copy number changes when compared to NTC-treated fibroblasts ([Fig. 7B](#F7){ref-type="fig"}). However, the topoIIα-depleted NHDFs displayed increased frequencies of gains and deletions of the *p16^INK4A^* allele. These results indicate that topoIIα is required for proper chromatid segregation during mitosis, and that decreased topoIIα levels and/or activity may generate or enhance the losses/gains of the tumor suppressor *p16^INK4A^* genetic locus. Collectively, these results suggest that topoIIα is required to maintain a barrier against tumor initiation and/or progression.

Due to the large increase in the number of abnormal interphase nuclei and the changes in the copy number of the *p16^INK4A^* genetic locus after topoIIα depletion, topoIIα-depleted NHDFs were examined for their ability to undergo clonal expansion. A clonogenic survival assay was performed in NHDFs after transient topoIIα depletion ([Fig. 7C](#F7){ref-type="fig"}). These results confirm that topoIIα is an essential gene with transient depletion of the protein reducing colony formation by an average of 68%. The colonies that escaped clonal inactivation after depletion of topoIIα may have arisen from cells that recovered topoIIα expression before lethality was manifested.

Discussion {#S10}
==========

The decatenation G~2~ checkpoint was originally proposed to delay entry into mitosis when chromosomes were insufficiently decatenated by topoII. Previous evidence for this checkpoint was largely derived from pharmacologic analyses using topoII catalytic inhibitors, such as ICRF-193 ([@R22]; [@R18]). This study provides biological evidence for the existence of a decatenation G~2~ checkpoint that is molecularly distinct from the DNA damage G~2~ checkpoint in three genetically diverse NHDFs ([Fig. 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). The previous studies in which ICRF-193 triggered a DNA damage response in some cancer lines may have used cell lines with a lax decatenation G~2~ checkpoint response, such as some HeLa cell lines (Bower and Kaufmann, unpublished data). HeLa cells would therefore enter mitosis in the presence of catenated chromosomes, acquire dsbs upon mitotic exit, and thus trigger a γH2AX and DNA damage response.

TopoIIα-depleted mitotic cells displayed high frequencies of entangled and under-condensed chromosomes ([Figure 6A/B](#F6){ref-type="fig"}) similar to biological effects recognized in cells treated with ICRF-193 that escape the decatenation G~2~ checkpoint. Abnormal nuclear structures that arise upon failure of chromatid decatenation and subsequent mal-segregation were also observed in topoIIα-depleted fibroblasts ([Figure 6C/D](#F6){ref-type="fig"}), suggesting that the decatenation G~2~ checkpoint is required to prevent the breakage of sister chromatids during the metaphase/anaphase transition. Furthermore, ICRF-193 treatment failed to prevent mitotic entry in topoIIα-depleted cells, indicating that the topoIIα protein plays an important role during the G~2~/M transition. NHDFs that enter mitosis in the absence of topoIIα, and thus escape decatenation G~2~ checkpoint activation, displayed losses and gains of the *p16^INK4A^* tumor suppressor gene. Collectively, these observations suggest that attenuation of the decatenation G~2~ checkpoint is one mechanism by which genomic instability may be generated, leading to tumor initiation and/or progression.

Although topoIIα and topoIIβ have similar *in vitro* biochemical activities, the results herein imply that the physiological roles of these proteins are very different. This is not unexpected, given that previous studies have suggested an independent role for topoIIβ in repairing DNA crosslinks and dsb-induced transcription factor recruitment ([@R23]; [@R32]). Furthermore, the data above suggest that topoIIβ activity is sufficient for S phase progression in NHDFs, but insufficient for decatenation G~2~ checkpoint activation ([Fig. 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}).

Our results are comparable to other studies in that topoIIα appears to be required for condensation and segregation of daughter chromosomes, with little contribution by topoIIβ to this process. Targeted disruption of the *TOP2A* gene in the HT1080 fibrosarcoma line, siRNA depletion of topoIIα in HeLa cells, and DT40 conditional topoIIα-depleted avian B cells produced similar results ([@R13]; [@R31]; [@R35]). Recent reports also suggest that topoIIα may interact with MDC1 to enforce the decatenation G~2~ checkpoint ([@R40]), and that topoIIα can be SUMOylated to assist in centromere localization and proper chromosome segregation ([@R20]; [@R17]). However, none of these studies have addressed the role of the decatenation G~2~ checkpoint in genomic stability.

Since many dietary components are known topoII catalytic inhibitors/poisons ([@R3]; [@R4]; [@R5]), it is possible that successive rounds of bypassing the decatenation G~2~ checkpoint may be an important consideration for the study of tumor initiation and progression. As *TOP2A* allelic deletions have been observed in breast cancer patients, exposure to these dietary compounds may increase genomic instability in these cancers and accelerate tumor progression ([@R8]). A further understanding of the signaling mechanisms involved in the decatenation G~2~ checkpoint could potentially lead to the identification of early-stage biomarkers and new therapeutic targets for a subset of cancers.

Materials and Methods {#S11}
=====================

Experimental Design and Cell Culture {#S12}
------------------------------------

NHDFs were described previously ([@R50]). Each fibroblast line was isolated from a different individual and underwent \<100 population doublings. Experiments were performed in all three NHDF lines to assess biological reproducibility and inter-individual genetic variation. NHDFs were grown in DMEM/10% FBS/2 mM L-Glutamine and maintained at 5% CO~2~ and 37°C. Periodic tests for mycoplasma contamination using a commercial kit (Gen-Probe, San Diego, CA) were negative.

In vitro Decatenation Assay {#S13}
---------------------------

10^7^ fibroblasts were fractionated with a ProtoJET Nuclear Extraction Kit (Fermentas, Inc., Glen Burnie, MD). Nuclear extracts were assayed for decatenatory activity using the TopoGEN Eukaryotic TopoII Assay kit (TopoGEN, Inc., Port Orange, FL). kDNA was electrophoresed in a 1% agarose gel to separate topoisomers, stained with SYBR Gold (Invitrogen, Carlsbad, CA), analyzed using a Typhoon 9400 (GE Healthcare, Piscataway, NJ), and quantified by ImageQuant TL v2005 Software (GE Healthcare).

Time Lapse Microscopy {#S14}
---------------------

NHDFs were treated with 0.1% DMSO or 4 μM ICRF-193 (Sigma, St. Louis, MO) at time zero. Bright-field time-lapse images were captured every two minutes at the Michael Hooker Microscopy Facility (MHMF) and the Microscopy Services Laboratory Core Facility at UNC-CH.

Immunofluorescence and γH2AX Flow Cytometry {#S15}
-------------------------------------------

NHDFs plated on coverslips were treated for 0, 0.25, 2, or 6 h with 4--12 μM Etoposide, 4 μM ICRF-193, or 0.1% DMSO. Coverslips were removed and fixed with 95% ethanol:5% acetic acid. The remaining cells were analyzed by flow cytometry. Samples were stained with a Phospho-Ser139 H2AX antibody (Millipore, Billerica, MA) and an anti-mouse Texas Red secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Nuclei were counter-stained with DAPI. Images were obtained on a Leica DMIRB inverted fluorescence microscope at the MHMF. Flow cytometry samples were measured on a Dako CyAN ADP instrument at the Flow Cytometry Core Facility at UNC-CH and plots were analyzed using Summit 4.3 software. Percentages of γH2AX positive cells were plotted against time and linear regression slopes were calculated for each treatment group. Statistical analysis was performed using a Student's t-test.

Ionizing Radiation {#S16}
------------------

A Gamma Cell 40 Cs^137^ irradiation source was used for IR treatment. Mitotic index was determined by the flow cytometry protocol described below two hours after irradiation.

Electroporation of Fibroblasts {#S17}
------------------------------

The NTC (5′-UGGUUUACAU GUCGACUAA-3′), topoIIα (5′-CUGCCUGUUUAGUCGCUUUC A-3′), and topoIIβ (5′-GAAGUUGUCUGUUGAGAGAUU-3′) siRNA were obtained from Dharmacon (Dharmacon, Inc., Lafayette, CO). A second topoIIα siRNA was obtained from Invitrogen (5′-GAGAUGUCACUAAUGAUGACCAUUA-3′). NHDFs were electroporated using an NHDF Nucleofector Kit (Lonza, Basel, Switzerland), and assayed for biological effects 48 h post-electroporation. Protein depletion for each individual experiment was confirmed by western immunoblot at time of assay.

Western Immunoblot {#S18}
------------------

Standard immunoblotting techniques were used to detect expression of topoIIα and topoIIβ. Briefly, equal amounts of total cellular protein were electrophoresed on 7% SDS-PAGE gels and transferred to nitrocellulose membranes and blocked in 4% BSA/TBST. TopoIIα and topoII β antibodies were obtained from BD Biosciences (San Jose, CA). Secondary anti-mouse Cy3/Cy5 antibodies were obtained from GE Healthcare and fluorescence was measured on a Typhoon 9400. Quantification of protein expression was performed using ImageQuant TL.

Flow Cytometric Mitotic Entry Assay {#S19}
-----------------------------------

Electroporated fibroblasts were plated at a density of 10^6^ cells (day 0), and fed with fresh medium on day 1. On day 2, cells were treated with 100 ng/mL colcemid and either 0.1% DMSO or 4 μM ICRF-193 for 2, 4, and 6 h. Fibroblasts were fixed with 95% ethanol:5% acetic acid. A phospho-Ser10 histone H3 primary antibody (Millipore) and a FITC-labeled secondary (Santa Cruz Biotechnology) were used to identify mitotic cells. Propidium iodide was used to measure DNA content. Summit 4.3 plots were used to quantify the percentage of NHDFs with 4N DNA content and phospho-Ser10 histone H3. The percentage of mitotic cells for each sample was plotted against time and the resulting slope of the line was used to measure the MER (% entering mitosis/hour).

Flow Cytometry BrdU Incorporation {#S20}
---------------------------------

Fibroblasts were incubated with 10 μM BrdU for 2 hours and fixed with 70% ethanol. An anti-BrdU-FITC antibody (BD Biosciences) was used to identify cells with actively replicating DNA. Propidium iodide was used to measure DNA content. Summit 4.3 plots were used to quantify the percentage of fibroblasts in G~0~/G~1~, S, and G~2~/M.

Cytogenetic Studies {#S21}
-------------------

Fibroblasts were incubated with 100 ng/mL colcemid for 1 h, incubated in hypotonic KCl (75 mM), and fixed with 3:1 methanol:acetic acid. Nuclei were dropped onto microscope slides and Geimsa-stained for visualization ([@R33]). Metaphases were examined using an Olympus BH2 microscope with a SPOT RT camera. 50+ metaphases were scored for each treatment group/cell line. All analyses were performed blinded to sample identity.

Nuclear Abnormality Assessment {#S22}
------------------------------

NHF1-hTERT cells were electroporated with siRNA as described above and allowed to adhere to coverslips. After 48 h, the coverslips were fixed with 3:1 methanol:acetic acid and stained with DAPI. Coverslips were mounted onto slides and 1000+ interphase nuclei were analyzed in a blind manner for structural abnormalities (blebs, bridges, and micronuclei) at the MHMF.

Fluorescence in situ Hybridization (FISH) {#S23}
-----------------------------------------

A second set of cytogenetic metaphase preparations were artificially aged in 2X SSC/0.1% NP-40 for 30 min at 37°C, successively dehydrated in 70%, 85%, and 100% ethanol, and air dried. A Vysis LSI p16 (9p21) Spectrum Orange/CEP9 Spectrum Green probe (Abbott Molecular, Des Plaines, IL) was hybridized to metaphase preparations overnight using a Vysis HyBrite (Abbott Diagnostics, Abbott Park, IL) according to the probe manufacturer's instructions. Gene copy numbers were assessed in a blind manner for both the *p16^INK4A^* locus and the CEP9 locus for at least 100 interphase nuclei per sample.

Clonogenic Survival Assay {#S24}
-------------------------

Single cell suspensions of fibroblasts were electroporated with NTC, topoIIα-, or topoIIβ-directed siRNA as described. One thousand cells were plated in triplicate. Colonies were fed every 2--3 days with fresh medium and stained 14 days after electroporation with 0.05% crystal violet/40% methanol. Colonies with \>50 cells were counted ([@R56]).

Supplementary Material {#S25}
======================
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![TopoIIα enzymatic activity accounts for the majority of decatenatory activity in normal human fibroblasts\
**A.** Western immunoblot analysis showing topoIIα depletion 48 h after electroporation in three different normal human fibroblast lines with an average reduction in protein levels of 94%. TopoIIβ depletion averaged 75%. **B.** The catalytic topoII inhibitor ICRF-193 decreased the *in vitro* decatenatory activity of NHDF nuclear extracts. siRNA depletion of topoIIα ablated the decatenatory activity of nuclear extracts, whereas topoIIβ depletion had no effect on decatenatory activity. Results are representative of three independent experiments in three different NHDF cell lines.](nihms206661f1){#F1}

![Catalytic inhibition of topoIIα prevents entry into mitosis\
NHDFs were observed via time-lapse bright-field microscopy in the presence of DMSO (vehicle control) or the catalytic topoII inhibitor ICRF-193. Control cells continued to enter and exit mitosis throughout the 24 h period of observation. Black arrows indicate several mitotic cells in each frame. After addition of ICRF-193, all initial mitotic cells exited mitosis within 2--3 hours of topoII inhibition, and no new mitotic figures were observed up to 24 h after treatment (see full length movies at <http://top2a.med.unc.edu/jackie/home.html>.)](nihms206661f2){#F2}

![Catalytic inhibition of topoII with ICRF-193 does not induce phospho-H2AX foci in NHDFs\
**A.** NHF1-hTERTs were exposed to 0.1% DMSO, 4 μM ICRF-193, or 12 μM etoposide. Phospho-Ser 139 H2AX (γH2AX) foci were observed after a 15 min treatment with the topoII poison etoposide, which produces DNA dsbs. Catalytic inhibition of topoII with ICRF-193 did not induce detectable γH2AX foci in NHDFs. Representative images are shown at 200X and 1000X (inset). **B.** Quantification of the percentage of cells expressing γH2AX in three NHDF lines treated with 4 μ etoposide or 4 μM ICRF-193 by flow cytometry. γH2AX staining increased over time in the etoposide-treated cells. ICRF-193 did not produce any detectable γH2AX staining until 6 h after treatment, and the signal was variable among the different NHDF lines. NHF3-hTERT cells produced substantially more γH2AX staining than the other two fibroblast lines and exhibited higher background levels of γH2AX. Results are presented as an average of three different NHDF cell lines ± SEM. \* = p \< 0.05.](nihms206661f3){#F3}

![TopoIIα is required for the decatenation G~2~ checkpoint, but not for the DNA damage G~2~ checkpoint response\
**A.** Dual color flow cytometry using a mitosis-specific antibody directed towards phospho-Ser10 histone H3 and propidium iodide to analyze DNA content was employed to examine the G~2~ checkpoint response to catalytic inhibition of topoIIα. NHDFs depleted of topoIIα emptied mitosis 2 h after treatment with 1.5 Gy of IR. In contrast, topoIIα-depleted fibroblasts failed to empty mitosis 2 h after ICRF-193 treatment, and instead appeared to accumulate in mitosis. Results are representative of three independent experiments with NHF1-hTERTs. **B.** Quantification of flow cytometry results illustrated in Figure 4A. Results are the average of three independent experiments with NHF1-hTERTs. \* = p \< 0.0025. **C.** Depletion of topoIIα allows NHDFs to continuously enter mitosis in the presence of ICRF-193. The rate of mitotic entry of topoIIα-depleted NHDFs was approximately half the rate of those cells electroporated with NTC siRNA on average. TopoIIβ-depleted fibroblasts displayed similar mitotic entry rates and a similar response to ICRF-193 as the NTC-treated fibroblasts. The results depicted in the illustration are the average of three independent experiments with NHF3-hTERTs, and were robustly conserved in all three NHDFs (shown in [Fig. S3](#SD3){ref-type="supplementary-material"}). **D.** Rates of mitotic entry for NTC-, topoIIα-, and topoIIβ-depleted NHDFs. Mitotic entry rates were calculated as linear regression slopes from Fig. 4C. The ratios of the slopes (4 μM ICRF-193:0.1% DMSO) were used to determine the percentage of mitotic entry inhibition (1-ratio × 100%). Maximum and minimum values of inhibition were set at 100% and 0%, respectively. Results are an average of three independent experiments for each NHDF line. \* = p \< 0.005.](nihms206661f4){#F4}

![Depletion of topoII α or topoIIβ does not affect DNA replication or completion of S phase in NHDFs\
**A.** Representative flow cytometry images of NHF10-hTERTs analyze for the ability to incorporate BrdU and plotted against DNA content. BrdU-incorporating cells between 2N and 4N DNA content were designated as S phase cells. **B.** Total percentages of fibroblasts in G~0~/G~1~, S, or G~2~/M compartments in the presence or absence of topoIIα or topoIIβ. There was no statistically significant change in the percentage of cells found in G~1~ among the three groups of NHDFs. TopoIIα- -depleted NHDFs exhibited an increase in the percentage of G~2~/M fibroblasts compared to the NTC treated NHDFs. However, neither topoIIα- nor topoIIβ-depletion affected BrdU incorporation or initiated replication fork collapse due to replication stress (cells containing S phase DNA content but no longer incorporating BrdU). Results are presented as the average of three independent experiments, each using a different NHDF lines. \* = p\< 0.05.](nihms206661f5){#F5}

![NHDFs entering mitosis without topoIIα activity have abnormal metaphase chromosome morphology and exit mitosis with abnormal nuclear morphology\
**A.** Examples of NHDF metaphase spreads after NTC siRNA treatment and topoIIα depletion. Two phenotypes were observed in the topoIIα-depleted fibroblasts: under-condensation and entanglement. **B.** Quantification of metaphase spreads from NTC-, topoIIα-, and topoIIβ-depleted fibroblasts. Results are an average of three independent experiments, each using a different NHDF lines. At least 50 metaphase spreads per siRNA-depletion were analyzed in a blinded manner for each line. \* = p\< 0.0025. **C.** Examples of NHDF interphase nuclei and the types of abnormalities scored. **D.** Quantification of the abnormal interphase nuclei in cells treated with NTC, topoIIα, or topoIIβ siRNA. Approximately 33% and 14% of interphase nuclei were abnormal after topoIIα or topoIIβ depletion, respectively. Results are the average of three independent experiments in the NHF1-hTERT line. Greater than one thousand interphase nuclei per treatment were analyzed. \* = p \< 0.01.](nihms206661f6){#F6}

![TopoIIα-depleted NHDFs display allelic gains and losses of the tumor suppressor p16^INK4A^\
**A.** Examples of NHDF metaphase spreads and interphase nuclei after NTC and topoIIα depletion. The example of topoIIα-depletion depicts a bridged nucleus in which four copies of the *p16^INK4A^* allele and centromere 9 appear to undergo improper segregation to the spindle poles. **B.** Quantification of the number of *p16^INK4A^* and centromere 9 alleles in interphase nuclei from NTC-, topoIIα-, and topoIIβ-depleted fibroblasts. Results are an average of three independent blind experiments, one for each NHDF line. At least 100 interphase nuclei per siRNA-depletion were analyzed for each line. \* = p \< 0.05. **C.** NHDF lines were treated with NTC, topoIIα, or topoIIβ siRNA and assayed for clonogenic survival. Results are presented as an average of three different NHDF cell lines, assayed in triplicate, and expressed as a percentage of NTC siRNA. Individual colony forming efficiencies are also displayed.](nihms206661f7){#F7}
